Vaccines and Global Health: The Week in Review
16 April 2022 :: Issue 653
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Error! Reference source not found. :: Organization Announcements
:: Journal Watch
**Session 1 – Global & Regional Reports**

*Report from the WHO Department of Immunization, Vaccines & Biologicals*

- The speed of the COVID-19 vaccine rollout has been unprecedented with nearly every country introducing the vaccine in under 12 months.
- Available data of COVID-19 vaccine effectiveness against the Omicron variant generally show waning immunity against infection but high and more sustained effectiveness against severe disease and death, especially after booster doses. Data remain very limited for some of the WHO EUL vaccines.
- To date, 21 countries remain below 10% population coverage, leaving at high risk the most vulnerable populations. Among countries eligible for support through the COVAX Advance Market Commitment (AMC) strategy at least 43 have set population targets at 70% or higher and only a small number have targets below 40% of their population.
- However, available data indicate that coverage among the high priority groups is insufficient to provide the needed protection against severe disease and death. Health worker coverage is 65% overall, with coverage below 50% in some regions (Non-AMC member states), and coverage of older adults is 69% going as low as 24% in some regions.
- Disruptions to routine immunization programmes persist, including the ongoing delay of at least one campaign in 37 countries as of 10 January 2022, putting millions of children at risk of disease outbreaks. Large and disruptive outbreaks of measles have occurred in at least 19 countries during the past 12 months.
- COVID-19 vaccination response and investments offer important opportunities that are being leveraged to restore and strengthen immunization programmes and enhance their resilience.

**WHO Regional Updates**

- National immunization programmes in all six WHO regions were adversely impacted by the COVID-19 pandemic through declining immunization coverage and surveillance quality, though the magnitude of the impact varied between and within regions.
- The European region is also facing a challenge due to the ongoing war in Ukraine and the resulting large population displacement. The WHO Regional Office and partner agencies are taking measures to mitigate the risks of vaccine-preventable disease outbreaks such as measles, polio, and COVID-19, while also ensuring continued delivery of critical medical supplies and services.
- All countries are implementing measures to restore vaccination coverage, with several having identified innovative strategies for catch up vaccination.
- The rollout of COVID-19 vaccination is progressing in all regions, though vaccine uptake varies between and within regions and disproportionately lower vaccination coverage has been observed in low- and low-middle income countries. Vaccine hesitancy and low risk perception are further affecting the uptake of COVID-19 vaccination in several countries.
**Gavi report**

- Reaching the zero-dose children through the building of resilient health systems remains a top priority of the Alliance in the Gavi strategy 2021-2025 (Gavi 5.0) and is estimated to account for over half the incremental impact of Gavi investments during the strategy period.
- A funding window for the rollout of malaria vaccines will be opened in the second half of 2022 to enable initial vaccine introductions in 2023.
- Gavi expressed concern over the 13% decline of global HPV vaccine coverage in 2020 due to COVID-19 disruptions, attributing this issue primarily to school closures and limited supply. It was acknowledged that a recommendation for a single dose regimen has the potential to accelerate introductions and reduce operational costs and complexity.
- The COVAX facility has sufficient supply available for all AMC countries to achieve the WHO 70% coverage target by June 2022. The COVAX Vaccine Delivery Partnership is supporting countries to overcome barriers and to achieve national coverage targets.

**Session 2 – Immunization Agenda 2030 and catch-up vaccination**

- SAGE was presented with evidence of the impact of the COVID-19 pandemic on national immunization programmes mainly due to service delivery disruptions.
- The urgent need to close resulting immunity gaps was recognized, as was the importance of supporting the recovery and resilience of immunization programmes and mitigating the risk of vaccine-preventable disease outbreaks.
- SAGE recommended that countries use the COVID-19 pandemic and COVID-19 vaccination rollout as a transformative opportunity to establish resilient immunization programmes and strengthen primary health care. Among the specific areas identified were health worker vaccination, immunization logistics and registries, surveillance, data and communications.
- The document “Guiding Principles for recovering, building resiliency, and strengthening of immunization in 2022 and beyond” was endorsed and recommended for dissemination to regional and national immunization technical advisory groups so that it may be adapted and used for their local context.

*[The full summaries for the sessions below are available at the PDF link above]*

**Session 3 – Hepatitis A vaccination**

**Session 4 – COVID-19 vaccines**

**Session 5 – Typhoid conjugate vaccination**

**Session 6 – Human Papillomavirus vaccination**

**Session 7 – Poliovirus vaccines**

---

**One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer**

11 April 2022

*News release*
The 4-7 April convening of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) evaluated the evidence that has been emerging over past years that single-dose schedules provide comparable efficacy to the two or three-dose regimens.

**SAGE’s review concluded that a single-dose Human Papillomavirus (HPV) vaccine delivers solid protection against HPV, the virus that causes cervical cancer, that is comparable to 2-dose schedules.** This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls...

“The HPV vaccine is highly effective for the prevention of HPV serotypes 16 & 18, which cause 70% of cervical cancer,” said Dr Alejandro Cravioto, SAGE Chair. “SAGE urges all countries to introduce HPV vaccines and prioritize multi-age cohort catch up of missed and older cohorts of girls. These recommendations will enable more girls and women to be vaccinated and thus preventing them from having cervical cancer and all its consequences over the course of their lifetimes.”

**SAGE recommends updating dose schedules for HPV as follows:**
- one or two-dose schedule for the primary target of girls aged 9-14
- one or two-dose schedule for young women aged 15-20
- Two doses with a 6-month interval for women older than 21.

Immunocompromised individuals, including those with HIV, should receive three doses if feasible, and if not at least two doses. There is limited evidence regarding the efficacy of a single dose in this group.

WHO’s recommendations will be updated following further consultation across stakeholders...

Globally, the uptake of the life-saving vaccine has been slow, and coverage in countries much lower than the 90% target. Consequently, in 2020 global coverage with 2 doses was only 13%. Several factors have influenced the slow uptake and low coverage of HPV vaccines including supply challenges, as well as the programmatic challenges and costs related to delivering a two regimen to older girls who are not typically part of childhood vaccination programs. Added to this has been the relatively high cost of HPV vaccines, particularly for middle-income countries...

The option for a single dose of the vaccine is less costly, less resource intensive and easier to administer. It facilitates implementing catch-up campaigns for multiple age groups, reduces the challenges linked to tracing girls for their second dose and allows for financial and human resources to be redirected to other health priorities.”

+++++
+++++

**COVID - IHR (2005 Emergency Committee**

**Statement on the eleventh meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic**

13 April 2022

Statement [Excerpts]
The eleventh meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (2005) (IHR) regarding the coronavirus disease (COVID-19) pandemic took place on Monday 11 April 2022...

The Secretariat presented on the current status of the COVID-19 pandemic and a vision for how to optimize the ongoing response to the COVID-19 pandemic for 2022. The presentation focused on:
- the global epidemiological context and factors that continue to drive transmission;
- updates on international traffic as well as COVID-19 proof of vaccination and test result certificates;
- the status of COVID-19 vaccination; and
- the strategic objectives for countries to incorporate in their COVID-19 response.

The Committee discussed key issues including SARS-CoV-2 variants; use and equitable access to antivirals; vaccine protection and global shifts in the supply and demand for COVID-19 vaccines; hybrid immunity; potential future scenarios for SARS-CoV-2 transmission and challenges posed by concurrent health emergencies; and how Member States are responding to the COVID-19 pandemic. The Committee also noted with concern the growing fatigue among communities worldwide in response to the COVID-19 pandemic and challenges posed by the lack of trust in scientific guidance and governments....

The Committee unanimously agreed that the COVID-19 pandemic still constitutes an extraordinary event that continues to adversely affect the health of populations around the world, poses an ongoing risk of international spread and interference with international traffic, and requires a coordinated international response. The Committee stressed the importance for States Parties to prepare for future scenarios with the assistance of WHO and to continue robust use of the essential tools (e.g. vaccines, therapeutics, and diagnostics). The Committee concurred that the COVID-19 pandemic remains a PHEIC and offered its advice to the Director-General.

The Director-General determined that the COVID-19 pandemic continues to constitute a PHEIC. He accepted the advice of the Committee and issued the Committee’s advice to States Parties as Temporary Recommendations under the IHR.

The Emergency Committee will be reconvened within three months or earlier, at the discretion of the Director-General. The Director-General thanked the Committee for its work.

---

**Equitable access to COVID-19 vaccination is a humanitarian imperative** - ICRC

*Statement by the International Committee of the Red Cross (ICRC) at the United Nations Security Council, New York 11 April 2022. Delivered by Dr. Esperanza Martinez, Senior Advisor to the Office of the Director-General*

12-04-2022 | Statement

Mr. President, Members of the Council, Colleagues,
Thank you for the opportunity to address you today and to the UK for spotlighting the importance of vaccination in conflict settings through Resolution 2565 as well as continuing the Council’s focus on what needs to be done.
COVID-19 has killed more than 6 million people globally – with the number probably much higher as these are only the officially reported figures. The successes in the development and production of vaccines mean that many countries are starting to regain a sense of normalcy. However, to end the pandemic, vaccination needs to occur everywhere – and this is not the case in conflict-affected areas.

In conflict-settings, health systems torn apart by conflict are less able to contain the spread of diseases across frontlines and international borders. Vaccination and other health activities in such contexts are incredibly difficult to carry out. Furthermore, many people in conflict settings are overlooked in public health responses, including people displaced, detained, or living in areas controlled by non-state armed groups.

Moreover, in areas affected by armed conflict, COVID-19 is not the most pressing issue. People face as the most basic needs – such as food, water, and shelter – are often not covered. Even if the health system continues to function, its focus turns from general health care, including vaccination, to treating war-wounded patients and keeping the core of the system functioning. This can happen in any conflict setting.

Mr. President,

The good news is that, as the supply of vaccine doses grows, the potential to get jabs in arms grows too. To achieve this in conflict settings, the International Committee of the Red Cross presents three asks to this Council, UN Member States, and conflict-affected countries:

First, ensure that International Humanitarian Law is respected
Under international humanitarian law, hospitals and other medical facilities as well as medical personnel – including those administering vaccines – are specifically protected from attacks. And where states cannot meet the basic needs of populations, they must allow impartial humanitarian organizations to conduct health activities – including vaccination.

These obligations are reaffirmed in Resolution 2565. We call on all parties to conflict to implement them in good faith as attacks on healthcare have a profound effect on people's lives and future.

Second, integrate COVID-19 vaccinations into a broader health strategy and in tandem strengthen the health system
We have seen vaccines expire on airport tarmacs in Afghanistan, Nigeria, South Sudan, and several other places. Some of these vaccines were wasted because they arrived with too short expiry dates. Others, because the receiving countries' health systems were not ready to distribute them. Countries need a degree of capacity to deliver vaccines.

The COVID-19 pandemic offers an opportune moment to strengthen the health systems in conflict-affected countries. We need to consider how COVID-19 vaccinations can be routinized where possible and integrated with other health services that are prioritized during times of conflict.

This doesn't mean we have to do everything, but we must invest in country preparedness and fortify the building blocks of the health system that support immunizations – and which in turn support the response to other pre-existing health needs. Critically, this investment can help address renewed outbreaks of other highly contagious and lethal diseases – which are occurring today, for example with measles in Afghanistan and polio in the Democratic Republic of Congo.
One strategy to address this is to invest in developing health workers' capacity and skillsets – as well as improving key components of service delivery, such as local supply chains and infrastructure. This is both critical and doable in contexts affected by armed conflict. The ICRC, for example, supported more than 600 health facilities in Iraq in 2021 which allowed the administration of over 14 million doses of COVID-19 vaccines.

Third, involve the community in vaccination activities and adequately resource community-engagement

Done well, effective community engagement is a force multiplier. It enhances the safety of frontline health workers and expands the reach of vaccination and other health efforts. Community involvement allows the community to identify pressing needs, take ownership, and spread the word about health-related programs.

For example, the ICRC established a network of Community Health Committees attached to 28 Primary Health Care Centres in Somalia and 16 in South Sudan. Many representatives are women from the community who can play an important role in the control and prevention of the COVID-19 pandemic and other diseases.

However, done poorly, ineffective or lack of community engagement can undermine public trust in vaccinations and government-run programs more broadly, with ramifications beyond this pandemic. We have witnessed the effects of distrust in West Africa with Ebola and now in many countries with COVID-19. Even if communities can be reached, people will not accept being vaccinated if they do not trust those administering the vaccine, and they do not see other pressing priorities being addressed.

For the ICRC and the wider Red Cross and Red Crescent Movement, community engagement ensures that communities' insights are an integral part of the design and delivery of programs, and that people have accurate information about vaccines and public health interventions, so they can make informed choices for themselves. Beyond vaccination, the ICRC strives to build trust with communities and parties to conflict concerning all its humanitarian activities.

The ICRC – as part of the Red Cross and Red Crescent Movement – will continue to play its part. The ICRC helped to administer more than 21 million doses of COVID-19 vaccines last year in areas impacted by armed conflict.

And we continue our offer of services to support states to implement their vaccination plans, to support National Red Cross and Red Crescent Societies as humanitarian auxiliaries, and to act as a neutral intermediary to facilitate access to vaccines and vaccination activities in hard-to-reach areas.

Equitable access to COVID-19 vaccination is a humanitarian imperative. Our collective recovery depends on it, because the longer COVID circulates anywhere, the longer it remains a threat everywhere.

UNICEF - COVID Vaccines

"We must take the rapid action needed to accelerate vaccination."
As prepared.

..."Just over 1 million cases of COVID-19 were reported to WHO in the last 24 hours - the pandemic is still far from over. We have safe and available vaccines that can protect against death and severe illness caused by COVID-19 and help avoid the next variant and there is an urgency, with over six million lives having been lost to date, to raise COVID-19 vaccination in countries that did not have this opportunity in 2021. **The next six months are critical.**

"More than 11.1 billion doses of COVID-19 vaccines have been administered globally:
:: 124 of the 194 WHO member states have vaccinated more than 40% of their population
:: 51 countries have reached more than 70% of their population; only 11% in low-income countries.
:: 83% of the population in WHO’s Africa region and 51% in its Eastern Mediterranean region, which includes Afghanistan, remain unvaccinated.

"In 2022, we must take the rapid action needed to accelerate vaccination. The window of opportunity is gradually closing. We risk losing the momentum and failing on vaccine equity.

"The COVID-19 Vaccine Delivery Partnership is focused, amongst others, on 34 countries which were at 10% or less full vaccine coverage and face the biggest challenges to increasing vaccination coverage. The goal is to vaccinate all adults and adolescents – starting with the elderly, healthcare and other frontline workers and those with underlying health conditions who are at the highest risk from COVID-19.

"19 of the 34 countries identified for concerted support by the Delivery Partnership are included in the Global Humanitarian Overview for 2022.

"We know there are many competing health, humanitarian and economic priorities in these countries. We must therefore **use every opportunity to bundle or integrate COVID-19 vaccination with other health and humanitarian interventions** and leverage these investments for the longer term strengthening of health systems.

"In many countries, COVID-19 vaccination is being integrated with measles campaigns and, in complement, with maternal health and routine immunization. COVID-19 vaccination is being used to strengthen cold chain, health management information systems and to train and provide incentives to health workers, including the surge required.

"With strong political leadership, country coordination and planning, and implementation of mass vaccination campaigns, countries can quickly pick up their vaccination rates and coverage. Since January 2022, the number of countries with a full population vaccination coverage rate at or below 10% has dropped from 34 countries to 18 countries currently...

..."I am speaking to you now from the Democratic Republic of the Congo where this week we will be meeting the government and key partners to better address the urgent bottlenecks to expanding vaccination coverage across this country of nearly 100 million people. We know Risk Communications and Community Engagement is a key component to success so we will be working with in-country
partners to support clear communications to increase demand and work to improve convenient access to vaccination.

“In humanitarian settings, from Afghanistan to Yemen, addressing low vaccination rates requires integrating with humanitarian priorities, working with humanitarian partners and a sustained, country-by-country effort to identify and overcome the primary obstacles to increasing vaccination rates among the populations affected by natural disasters, conflict and socio-political instability.

“We recognize the significance of the Humanitarian Buffer, a mechanism established within the COVAX facility to ensure access to COVID-19 vaccines for high-risk and vulnerable populations living in humanitarian settings. As of today, two applicants have successfully received vaccine doses via the Humanitarian Buffer -- the Ministries of Health in Iran and Uganda -- but the partners are committed to make it a more user friendly, easily accessible mechanism to ensure that humanitarian populations not included in national vaccination plans, microplanning, or the implementation process can equally benefit from vaccination.

“The COVID-19 Vaccine Delivery Partnership and partners -- UNICEF, WHO, GAVI, the World Bank, the Africa CDC and others -- are providing concerted support to all these countries, mobilizing political engagement, providing flexible funding ($21 million in last two months), strategic advice and technical assistance. We are lining up partners behind one country team, one plan and one budget to put countries at the center and reduce their transaction costs.

“Mr President, Excellencies, to address the significant vaccine equity gap that continues to pose a threat for global health security, please consider the following requests:

"First, continue your strong support and actions to implement Resolutions 2532 and 2565 with a particular focus on ensuring countries continue to prioritise COVID-19 vaccination.

"Second, with appreciation for the US$4.8 billion in pledges made at the COVAX AMC summit co-hosted with Germany, turn these commitments into support for lower-income countries’ COVID-19 vaccination needs, with a priority on delivery systems. Flexible, agile funding is vital and these investments can last beyond the pandemic.

"Third, advocate for and help guarantee full, safe and unhindered access, in line with International Humanitarian Law -- including protecting humanitarian corridors -- as a means to getting vital supplies of vaccines and other essential equipment for the delivery of COVID-19 vaccinations to populations in need and ensure the safety of health and humanitarian personnel administering vaccines in humanitarian settings.

"Fourth, advocate across government, and work with UN country teams and partners to ensure strong national vaccination planning that addresses the needs of all populations living within the national territory, regardless of nationality, migration or refugee status.

"Fifth, engage in the important conversations on the global health emergency architecture and advocate for strong governance and an investment in the basics of primary health care as a key element of future pandemic preparedness.”
WHO, WIPO, WTO launch trilateral COVID-19 technical assistance platform
11 April 2022
The World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO launched on 11 April 2022 their new Trilateral COVID-19 Technical Assistance Platform. This new tool aims to help members and WTO accession candidates address their capacity building needs to respond to the COVID-19 pandemic.

In welcoming the initiative, WTO Director-General Okonjo-Iweala said the Platform “takes our trilateral collaboration to the next level: a one-stop shop for members to seek and receive support from the three organizations on all available tools including intellectual property flexibilities to improve access to COVID-19 vaccines, medicines, and related technologies.”

WHO Director-General Tedros Adhanom Ghebreyesus said: “The WHO-WIPO-WTO partnership aims to place public health innovation and intellectual property at the service of access to health technologies for everyone. Countries should consider using this platform and all other available mechanisms to promote public health.”

WIPO Director General Daren Tang noted the three organizations “came together last summer to offer our expertise and resources jointly to help members overcome the complex challenges posed by the pandemic. I am proud that through our partnership, we are providing a Trilateral Technical Assistance Platform that gives members a ‘one-stop shop’ access to the expertise and resources of all three organizations. By working together to support the strengthening of innovation, trade and health, we can help members overcome and recover.”

The new Platform for COVID-19 related technical assistance provides WTO members and accession candidates an overview of technical assistance activities offered by the three organizations. It supports members and accession candidates seeking to address their needs for COVID-19 vaccines, medicines and related technologies and facilitates requests for the provision of timely and tailored technical assistance with a view to making full use of all available options...

COVID-19 vaccines and treatments output continues apace; as health systems and last mile hurdles remain - IFPMA
- To date, over 13 billion doses of COVID-19 vaccines have been produced and 11 billion have been administered. Presently, vaccine supplies outstrip global demand, with voluntary technology transfer playing a significant role. Urgent steps are needed to provide a high level of protection against COVID-19 among the elderly and vulnerable populations wherever they live.
- Several COVID-19 treatments are now standard of care for COVID-19. Biopharmaceutical companies with approved treatments are scaling up manufacturing capacity with wide use of voluntary licensing, but the effective roll out of treatments to all patients is dependent on swift regulatory approval, allocation strategies, health systems capacity, and testing.
- The historic scaling up of manufacturing and the numerous technology transfers and voluntary licenses are further proof that intellectual property has been an enabler throughout the pandemic. **Recent COVID-19 waves underscore that equitable access to vulnerable populations should be commanding all our collective efforts.**

13 April 2022, Geneva – The COVID-19 pandemic continues to evolve and challenge the public health response. Meanwhile, the biopharmaceutical industry continues to bring its R&D expertise and solutions to the pandemic, while scaling up manufacturing of safe and effective treatments and vaccines. **There is now broad acknowledgement that supplies of COVID-19 vaccines have outstripped demand, and manufacturing of treatments for people who have contracted COVID-19 or who are unable to be vaccinated is on track thanks, in part, to widespread voluntary licensing...**

To date, 13.7 billion COVID-19 vaccine doses have been delivered[1]. While 11 billion COVID-19 vaccines have been administered thus far, equitable distribution remains a major concern. The spread of the Omicron BA2 variant underscores the importance of targeted immunization and should focus all minds to ensure full course vaccinations are administered with haste to all in need, in particular the elderly, vulnerable populations, and people who are immunosuppressed.

**Sufficient vaccines are available to continue inoculation programs, since more than 7.98 billion doses could be produced this year.** More than half of the doses forecast to be produced this year will be COVID-19 vaccines produced by companies member of IFPMA, together with partners who are in technology transfer agreements with them. In parallel to COVID-19 vaccine manufacturing, innovation into broader spectrum vaccines to tackle the pandemic continues apace, with combination vaccines or vaccines that are easier to transport and administer.

The biopharmaceutical industry remains steadfast in its position that steps urgently need to be taken to ensure all healthcare workers, the elderly, and those who are immunosuppressed or vulnerable through comorbidities wherever they live should receive a full course of vaccines. “The trend that we predicted last year that COVID-19 vaccine supplies will outstrip global demand has been proven correct,” said Thomas Cueni, Director General, IFPMA. The COVID-19 vaccine manufacturing scale-up has seen 372 partnerships forged, of which 88% (329) include technology transfer or fill & finish. 51 manufacturing and production agreements were made in developing countries (LICs and LMICs).

In addition, several important commitments have been made by biopharmaceutical companies that are set to change Africa’s vaccine manufacturing landscape in years to come. “To continue to advocate that vaccine equity is caused by scarcity of vaccines due to a lack of technology transfer flies in the face of the facts – both for the numbers of vaccines available but also for the way vaccines are made. The reasons for the woeful inequity are manifold but cannot be laid at the door of intellectual property,” Cueni explained. “We remain steadfast in our verdict that the proposed World Trade Organization’s TRIPS waiver is a solution in search of a problem. It is a distraction and is misleading in its promise of equity for this pandemic. And it sends the wrong signal to innovators for future pandemics,” he concluded...

**There is increasing acceptance that society will have to live with COVID-19.** The vaccines and treatments that have been developed since the pandemic are essential public health tools to both alleviate the impact of the virus but also help people with other conditions access the care they need.
Continued innovation remains essential. Fortunately, there is a strong pipeline for both COVID-19 vaccines and treatments, building on the 10 vaccines that have so far received WHO EUL approval and the 18 different treatments that have been approved in the UK, USA, and EU.

Further innovation is critical to keep pace with the evolving nature of COVID-19. **Today, there are 271 vaccines in preclinical and 147 in clinical phases and there are 1827 treatment candidates in clinical trials.** Innovation is not without its risks; for example, so far 9 vaccine candidates that reached the final phase of clinical trials have been discontinued and 6 applications were rejected.


---

**COVAX Guidance, Analysis, Reports**

**Emergency use of unproven clinical interventions outside clinical trials: ethical considerations - WHO**

12 April 2022 :: 60 pages

**Overview**

This document is intended to provide policy-makers, authorities in charge of the prevention and management of a public health emergency, such as ministries of health, national regulatory authorities and national disaster management agencies, health-care workers, ethics committees and others, with:

- an updated version of the ethical framework for use of unproven clinical interventions outside clinical trials during public health emergencies (the MEURI ethical framework),
- general and operational recommendations for implementing the framework and
- answers to questions that stakeholders may raise.

**Table 2. Outline of WHO’s updated ethical framework for emergency use of unproven clinical interventions outside clinical trials (the MEURI ethical framework)**

<table>
<thead>
<tr>
<th>I. Justification</th>
<th>II. Ethical and regulatory oversight</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Public health emergency</td>
<td>6. Review and approval by authority and ethics committee</td>
</tr>
<tr>
<td>2. Absence of proven intervention</td>
<td>7. Minimization of risks</td>
</tr>
<tr>
<td>3. Impossibility of initiating research immediately</td>
<td>8. Responsible transition</td>
</tr>
<tr>
<td>4. Scientific support based on a favourable risk–benefit ratio</td>
<td>9. Fair access to scarce unproven interventions</td>
</tr>
<tr>
<td>5. Effective use of resources</td>
<td>10. Individual informed consent</td>
</tr>
<tr>
<td>11. Community engagement</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>III. Consent process</th>
<th>IV. Contribution to evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>10. Individual informed consent</td>
<td>12. Monitoring, collecting and sharing relevant data</td>
</tr>
</tbody>
</table>

**Equitable access to COVID-19 tools - WHO**

Aligning the private sector with national response efforts
COVID-19 has reinforced the need for whole-of-society and whole-of-government approaches to the pandemic response. This has tested the foundation of public and private sector relations in healthcare, and either nurtured or exacerbated trust. In many instances, the private sector has demonstrated solidarity and delivered critical essential and COVID-19-related health services and products. However adverse behaviours have also featured. These have exacerbated the State’s duty to ‘protect’ the right to health, improve health security and system resilience for universal health care. The pandemic has further exposed the need for robust governance of health systems. This is good for both the private and public sectors, but most importantly, consumers, including those most likely to be left behind. This rapid review seeks to understand why and where there has been swift and proactive action to build better governance of national COVID-19 response, to cross-countries lessons sharing on how to govern the private sector in health to maximize the COVID-19 response.

Coronavirus [COVID-19] - WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 14 Apr 2022
Confirmed cases :: 500 186 525
Confirmed deaths :: 6 190 349
Vaccine doses administered: 11 294 502 059

Weekly epidemiological update on COVID-19 - 12 April 2022
Overview
Globally, during the week of 4 through 10 April 2022, the number of new COVID-19 cases has continued to decline for the third consecutive week, with a 24% decrease as compared to the previous week. Also the number of new weekly deaths continue the decreasing trend (-18% as compared to the previous week).

Across the six WHO regions, over 7 million cases and over 22 000 deaths were reported, with all the regions showing decreasing trends both in the number of new weekly cases and new weekly deaths. As of 10 April 2022, over 496 million confirmed cases and over 6 million deaths have been reported globally.

In this edition we provide:
- Special Focus: Update on WHO COVID-19 global rapid risk assessment
- Updates on circulating SARS-CoV-2 variants of concern (VOCs), including information on Omicron descendent lineages.
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 April 2022

[New additions; Full scale view available at title link above]
[Updated on 16 Apr 2022]

COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases - No new company announcements identified

BioCubaFarma – Cuba
Últimas Noticias - Website not leading at inquiry

Biological E
News - No new digest announcements identified

Biontech
Press Releases
**Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age**
14 April 2022

**BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines**
11 April 2022

**CanSinoBIO**
*News* - Website not responding at inquiry

**CIGB**
*Latest News* - No new digest announcements identified

**Cinagen**
*Recent News* - No new digest announcements identified

**Clover Biopharmaceuticals** - China
*News* - No new digest announcements identified

**Curevac [Bayer Ag – Germany]**
*News*
April 11, 2022

**CureVac and GSK Enter into Pandemic Preparedness Contract with German Government**
- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK
- Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to increased pandemic preparedness

**Gamaleya National Center**
*Latest News and Events* - See Russia below.

**IMBCAMS**, China
*Home* - Website not responding at inquiry

**Janssen/JNJ**
*Press Releases* - No new digest announcements identified

**Medicago**
*Media* - No new digest announcements identified

**Moderna**
*Press Releases*
11 April, 2022

**Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates**

**Nanogen**
Novavax
Press Releases
Apr 13, 2022
Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

Pfizer
Recent Press Releases
04.14.2022
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralogy and Biotechnology
Home - No new digest announcements identified

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

GSK
Press releases for media - No new digest announcements identified
**Merck**

*News releases*

**Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults**

April 14, 2022

**Novartis**

*News* - *No new digest announcements identified*

**SK Biosciences**

*Press releases*

**SK bioscience Initiates Clinical Development of Antiviral Nasal Spray for Prevention of COVID-19**

- SK began developing an innovative technology to prevent viral infections and relieve symptoms through intranasal spray
- The spray is expected to be used as the first line of defense to prevent virus spread before vaccine development
- The project is being funded by the Bill & Melinda Gates Foundation through a grant to IAVI and a subgrant to SK bioscience

2022.04.13

**Valneva**

*Press Releases*

April 14, 2022

**Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine**


---

**UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 16 Apr 2022**

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]

<table>
<thead>
<tr>
<th></th>
<th>35</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccines approved for use by at least one national regulatory authority</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccines in WHO’s Emergency Use Listing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doses secured globally</td>
<td>17.8bn</td>
<td>$2-$40</td>
</tr>
<tr>
<td>Reported vaccine price range per dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doses COVAX has secured, optioned, or received as donations</td>
<td>2.8bn</td>
<td>1.43bn</td>
</tr>
<tr>
<td>Doses shipped through COVAX to 145 countries</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 16 Apr 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability
Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution.

[accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

16 Apr 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 500M total confirmed cases; 6.2M total confirmed deaths

Global vaccines administered: 11.4B

Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 280M
Other Delivered (Number of Doses): 260M
Total Delivered (Number of Doses): 540M
Total Administered (Number of Doses): 390M
**Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**

[https://data.covid19taskforce.com/data](https://data.covid19taskforce.com/data)

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.


---

**Our World in Data**

**Coronavirus (COVID-19) Vaccinations**  [Accessed 16 Apr 2022]

- **65%** of the world population has received at least one dose of a COVID-19 vaccine.  
  **11.45 billion doses** have been administered globally, and **11.79 million** are now administered each day.  
  Only **15.2%** of people in low-income countries have received at least one dose.
Share of people who completed the initial COVID-19 vaccination protocol, Apr 14, 2022

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

Source: Official data collated by Our World In Data - Last updated 15 April 2022, 11:00 (London time)
Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.
OurWorldInData.org/coronavirus • CC BY
U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

HHS
News
No new digest content identified.

BARDA-ASPR – U.S. Department of HHS  [to 16 Apr 2022]
https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx
News
Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of Coronavirus Disease 2019 (COVID-19) Pandemic
Tuesday, April 12, 2022

FDA
Press Announcements

FDA Takes Important Steps to Increase Racial and Ethnic Diversity in Clinical Trials
Agency’s Focus on Inclusion in Trials for All Medical Products Aligns with Biden Administration’s Cancer Moonshot Goal of Addressing Inequities and Beyond
April 13, 2022
Today, the U.S. Food and Drug Administration issued a new draft guidance to industry for developing plans to enroll more participants from underrepresented racial and ethnic populations in the U.S. into clinical trials – expanding on the agency’s previous guidances for industry to improve clinical trial diversity.

“The U.S. population has become increasingly diverse, and ensuring meaningful representation of racial and ethnic minorities in clinical trials for regulated medical products is fundamental to public health,” said FDA Commissioner Robert M. Califf, M.D. “Going forward, achieving greater diversity will be a key focus throughout the FDA to facilitate the development of better treatments and better ways to fight diseases that often disproportionately impact diverse communities. This guidance also further demonstrates how we support the Administration’s Cancer Moonshot goal of addressing inequities in cancer care, helping to ensure that every community in America has access to cutting-edge cancer diagnostics, therapeutics and clinical trials.”

Despite having a disproportionate burden for certain diseases, racial and ethnic minorities are frequently underrepresented in biomedical research. Clinical trials provide a crucial base of evidence for evaluating whether a medical product is safe and effective; therefore, enrollment in clinical trials should reflect the diversity of the population that is ultimately going to use the treatment. It is known that biological differences exist in how people respond to certain therapies. For example, variations in genetic coding can make a treatment more or less toxic for one racial or ethnic group than another.
These variations can also make drugs like antidepressants and blood-pressure medications less effective for certain groups.

This draft guidance, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials,” recommends that sponsors of medical products develop and submit a Race and Ethnicity Diversity Plan to the agency early in clinical development, based on a framework outlined in the guidance...

Regulatory Actions

**Vaccines and Related Biological Products Advisory Committee - FDA**

*Calendar*
No new calendar dates identified.

:::::::::

**White House [U.S.]** [to 16 Apr 2022]

*Briefing Room – Selected Major COVID Announcements*
*Press Statement - COVID Context*
No new digest content identified.

**U.S. Department of State** [to 16 Apr 2022]
https://www.state.gov/coronavirus/releases/

*Press Statement - COVID Context*
No new digest content identified.

**USAID** [to 16 Apr 2022]

*Selected Press Releases, Statements, Announcements*

**USAID Announces New Programs to Protect Our Ocean**
April 14, 2022
Press Release
The U.S. Agency for International Development (USAID) announced 24 initiatives to protect our ocean at the Our Ocean Conference 2022 in Palau.

**USAID Announces $18 Million Contribution to Education Cannot Wait**
April 13, 2022
Press Release
The U.S. Agency for International Development (USAID) will contribute an additional $18 million to Education Cannot Wait (ECW), the major global fund for education in emergencies. USAID announced the additional funding during ECW’s scoping visit to Moldova to support the response to the crisis in Ukraine.

**USAID and LIXIL Announce $10 Million to Confront the Global Sanitation Crisis**
April 12, 2022

Today, the U.S. Agency for International Development and LIXIL, a global housing and sanitation products multinational company, launched the Partnership for Better Living to expand access to affordable sanitation and hygiene solutions for the underserved in up to 11 countries across sub-Saharan Africa and Asia by 2026.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency
News & Press Releases
Press Releases
[No new digest content identified]

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates [Selected]
[No new digest content identified]

---

**Cumulative vaccine uptake (%) in the total population in EU/EEA countries**

<table>
<thead>
<tr>
<th>At least one dose</th>
<th>Primary course</th>
<th>Booster/additional dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>75.3%</td>
<td>72.5%</td>
<td>52.9%</td>
</tr>
</tbody>
</table>

Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-04-13

Accessed 16 Apr 2022

---

European Commission
https://ec.europa.eu/commission/presscorner/home/en
Latest [Selected]
Press release 14 April 2022
**Green Deal: EU announces €1 billion worth of commitments to protect the ocean**

Today, at the Our Ocean Conference (OOC) in Palau, the EU has renewed its pledges towards international Ocean governance.

Press release 12 April 2022
**Ukraine: EU humanitarian operation in the Republic of Moldova enhances assistance for refugees**

Since the start of Russia's invasion on 24 February, the refugee influx of civilians fleeing Ukraine to reach neighbouring countries has resulted in skyrocketing humanitarian needs.

Press release 9 April 2022
**Stand Up For Ukraine: €9.1 billion pledged in support of internally displaced and refugees**

The “Stand Up for Ukraine” global pledging event and campaign has raised €9.1 billion for people fleeing the Russian invasion, inside Ukraine and abroad, including €1 billion from the European Commission.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/

Press Releases
Latest Updates [Selected]
[No new digest content identified]

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Government of India – Press Information Bureau
Latest Press Releases
COVID - 19 Vaccination Update - Day 456
:: India’s cumulative vaccination coverage crosses 186.49 Crore
:: More than 11 lakh Vaccine doses administered today till 7 pm
:: More than 2.42 Crore Vaccine Doses administered to 12-14 age group so far
Posted On: 16 APR 2022 8:05PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.
China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify official announcements about Shanghai confirming the reports below; See China CDC below for additional announcements]

China tightens controls as Shanghai reports record Covid cases

Japan urges local government to address business concerns as ongoing restrictions hit commerce

Reuters in Shanghai
Sat 16 Apr 2022 10.42 EDT
Shanghai reported a record number of symptomatic Covid-19 cases on Saturday and other areas across China tightened controls as the country kept up its “dynamic clearance” approach that aims to stamp out the highly transmissible Omicron variant.

The Zhengzhou airport economic zone, a central Chinese manufacturing area that includes Apple supplier Foxconn, announced a 14-day lockdown on Friday “to be adjusted according to the epidemic situation”...

...Shanghai itself, which is at the centre of China’s recent Covid surge starting in early March, reported a record 3,590 symptomatic cases for 15 April, as well as 19,923 asymptomatic cases. The asymptomatic case number was up slightly from 19,872 cases a day earlier.

The city’s case tally makes up the vast majority of cases nationwide even as most of its 25 million residents remain under lockdown...

At the Zhengzhou economic zone, only personnel with valid passes, health codes and proof of negative Covid tests would be able to leave during the two-week period, although “special vehicles” would be able to travel normally for work reasons, local authorities said in a post on an official WeChat instant messaging account.

Overall, China reported 24,791 new coronavirus cases on 15 April, of which 3,896 were symptomatic and 20,895 were asymptomatic, the National Health Commission said on Saturday.

::::::
::::::

UN OCHA – Current Emergencies

Current Corporate Emergencies

Afghanistan

No new updates identified.

Northern Ethiopia

Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 14 Apr 2022

HIGHLIGHTS
- Humanitarian partners have not been able to move any additional aid supplies into Tigray by road since the convoy entered on 1 and 2 April.
- About 36 metric tons of HIV medical supplies were airlifted to Mekelle, the first time since July 2021. It will be enough to provide treatment for 46,000 patients for six months.
- Authorities in Amhara relocated more than 20,000 people out of the planned 70,000 people in North Wello and Wag Hamra zones to new designated sites since mid-March.
- WFP assisted over 35,000 people with food in Gulina, Barahle and Dalole woredas in Afar during the reporting period, reaching over 235,000 people since last week of February.
- More than 11,000 children under five and pregnant and lactating women received supplementary nutrients in Wag Harma and North Wello zones in Amhara between 1 and 10 April.

**Ukraine**

**Ukraine: Humanitarian Impact Situation Report (As of 12:00 p.m. (EET) on 15 April 2022)**

---

**WHO & Regional Offices** [to 16 Apr 2022]
https://www.who.int/news

*News [Selected]*
14 April 2022
Departmental news

**The Global Diabetes Compact: a promising first year**

14 April 2022
Departmental news

**World Chagas Disease Day: finding and reporting every case**

13 April 2022
Statement

**Statement on the eleventh meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic**

[See Milestones above for detail]

13 April 2022
Departmental news

**Ukraine next country to receive technology from the WHO mRNA technology transfer hub**

12 April 2022
Departmental news

**Meeting of WHO Director-General's Expert Group on Cervical Cancer Elimination, 19 April 2022**

11 April 2022
Departmental news

**SAGE April 2022 meeting highlights**

[See Milestones above for detail]

11 April 2022
Departmental news

**WHO, WIPO, WTO launch trilateral COVID-19 technical assistance platform**
One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer
[See Milestones above for detail]

WHO Director General Speeches [selected]
https://www.who.int/director-general/speeches
Selected
14 April 2022
Speech
WHO Director-General's opening remarks on Member State Information Session on COVID-19 - 14 April 2022

14 April 2022
Speech
WHO Director-General's opening remarks at the Briefing to the African Union Ambassadors in Geneva on Strengthening Local Manufacturing Capacity – 14 April 2022

13 April 2022
Speech
WHO Director-General's opening remarks at the WHO press conference – 13 April 2022

12 April 2022
Speech
WHO Director-General's opening remarks at the International Strategic Dialogue on Noncommunicable Diseases and the Sustainable Development Goals – 12 April 2022

12 April 2022
Speech
WHO Director-General's opening remarks at the Global Launch of the WHO QualityRights e-training to advance mental health, eliminate stigma and promote community inclusion – 12 April 2022

12 April 2022
Speech
WHO Director-General's opening remarks at the Public Hearing regarding a new international instrument on pandemic preparedness and response – 12 April 2022

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region
:: Africa witnesses longest-running decline in COVID-19 cases 14 April 2022
Brazzaville – Africa is experiencing its longest-running decline in COVID-19 infections since the onset of the pandemic. Recorded weekly cases have fallen for the past 16 weeks, while deaths have dropped for the last eight.

Infections—largely due to the Omicron-driven fourth pandemic wave—have tanked from a peak of over 308,000 cases weekly at the start of the year to less than 20,000 in the week ending on 10 April 2022. Over the past week, around 18,000 cases and 239 deaths were recorded, a decline of 29% and 37% respectively compared with the week before. This low level of infection has not been seen since April 2020 in the early stages of the pandemic in Africa...

:: Botswana, South Africa deepen probe into new Omicron sub-variants 12 April 2022

Brazzaville – Researchers in Botswana and South Africa have detected new sub-lineages of the Omicron variant of the SARS-CoV-2 and are carrying out further investigations to fully understand crucial traits such as infectivity and virulence.

The identified sub-lineages variant are BA.4 and BA.5. World Health Organization (WHO) experts are working with scientists and researchers in the two countries to deepen analysis of the sub-lineages which have so far been identified in four people in Botswana and 23 in South Africa. Outside Africa, the BA.4 and the BA.5 have been confirmed in Belgium, Denmark, Germany and the United Kingdom...

:: Deaths from noncommunicable diseases on the rise in Africa 11 April 2022

Accra/Brazzaville – Noncommunicable diseases such as cancer, cardiovascular diseases and diabetes are increasingly becoming the main cause of mortality in sub-Saharan Africa, where the diseases were responsible for 37% of deaths in 2019, rising from 24% in 2000 largely due to weaknesses in the implementation of critical control measures including prevention, diagnosis and care. This comes on the eve of a high-level heads of state and health leaders meeting in Ghana to find ways of accelerating progress against noncommunicable diseases...

WHO Region of the Americas PAHO

:: 13 Apr 2022

Less than 10% of those infected with Chagas disease receive timely diagnosis and treatment

PAHO calls for detection of all cases and equitable access to care for this disease, which causes about 30,000 new infections each year. Washington, DC, April 13, 2022 (PAHO)- Due to its silent nature, less than 10% of those infected with Chagas disease each year receive timely diagnosis and, therefore, effective treatment in Mexico, Central...

:: 11 Apr 2022

One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer

Geneva, 11 April 2022 (WHO)- The 4-7 April convening of the WHO Strategic Advisory Group of Experts on Immunization (SAGE) evaluated the evidence that has been emerging over past years that single-dose schedules provide comparable efficacy to the two or three-dose regimens. SAGE’s review concluded that a single-dose Human Papillomavirus (HPV)...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: Regional Director pledges WHO support to help Ukraine’s health system build back better during visit to Lviv 13-04-2022

:: Adjusting health financing for people fleeing conflict: WHO releases new guidance for countries in Europe 13-04-2022

:: ‘Ensuring high-quality of HIV Care for displaced people from Ukraine’ 13-04-2022
Novo Nordisk Foundation supports WHO’s emergency response in Ukraine and neighbouring countries with 25 million Danish kroner/3.4 million euros 13-04-2022

WHO Eastern Mediterranean Region EMRO
:: Taking the battle against malaria to its source – the mosquito 14 April 2022
:: WHO and KSrelief join efforts in the fight against child malnutrition in Yemen 13 April 2022
:: WHO delivers rapid antigen tests for COVID-19 to Iraq 11 April 2022

WHO Western Pacific Region
No new digest content identified.

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

15 April 2022 | Circulating vaccine-derived poliovirus type 3 – Israel

15 April 2022 | Acute hepatitis of unknown aetiology – the United Kingdom of Great Britain and Northern Ireland

WHO Events
https://www.who.int/news-room/events/1
[Selected]

WHO Public Health Laboratories knowledge sharing webinars - Genomic surveillance and building up Next Generation Sequencing capacity
20 April 2022 11:00 – 12:30 CET

World Immunization Week
World Immunization Week 2022 - Long Life for All
24 – 30 April 2022

World Malaria Day 2022 - Harness innovation to reduce the malaria disease burden and save lives
25 April 2022

10th ACT-Accelerator Facilitation Council meeting
26 April 2022 12:30 – 15:00 CET

New WHO Publications
https://www.who.int/publications/i
Selected Titles
14 April 2022
Environmental surveillance for SARS-COV-2 to complement public health surveillance – Interim Guidance

Overview
Routine diagnostic surveillance for COVID-19 has been augmented with environmental surveillance (ES) in wastewater in many locations. ES provides additional evidence on virus in circulation at population level including presence or absence, early warning of increasing or decreasing trends, and information on variants of concern or interest.

This guidance provides advice on:
- What situations ES has been shown to add value to public health decision making
- What is needed to plan and coordinate an effective ES programme
- How to carry out data collection, analysis, interpretation and communication of results.

This guidance is targeted at public health officials who want to understand and integrate complementary ES into COVID-19 control strategies.

14 April 2022
Emergency in Ukraine: external situation report #7, published 14 April 2022: reporting period: 7–13 April...

13 April 2022
INSPIRE: seven strategies for ending violence against children: uptake between 2016 and 2021

13 April 2022
Health system performance assessment

12 April 2022
Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis...

12 April 2022
WHO Expert Committee on Biological Standardization: seventy-fourth report

12 April 2022
Emergency use of unproven clinical interventions outside clinical trials: ethical considerations
[See COVID above for detail]

12 April 2022
Ethics and medical radiological imaging: a policy brief for health-care providers

12 April 2022
Towards better engagement of the private sector in health service delivery

12 April 2022
Equitable access to COVID-19 tools
[See COVID above for detail]

11 April 2022
How to temperature map cold chain equipment and storage areas

11 April 2022

Noncommunicable Diseases Progress Monitor 2022

CDC/ACIP [U.S.] [to 16 Apr 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Tuesday, April 12, 2022
CDC Media Telebriefing: 2020 STD Surveillance Report

ACIP Meetings
Next ACIP Meeting
April 20, 2022 11:00am – 4:00pm ET.
This meeting is virtual. No registration is required to watch the webcasts.
Webcast Link
No Agenda posted at inquiry

MMWR Weekly: Current Volume (71) April 15, 2022 / No. 15
PDF of this issue
- Surveillance to Track Progress Toward Polio Eradication — Worldwide, 2020–2021
- COVID-19 Mortality and Vaccine Coverage — Hong Kong Special Administrative Region, China, January 6, 2022–March 21, 2022
- Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022

Coronavirus Disease 2019 (COVID-19)- CDC
Approximately 25 announcements/reports/data summaries.
:: 4/15/22   Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 15 Apr 2022 06:00:00 EST
:: 4/15/22   Recommendations for Tribal Ceremonies and Gatherings During the COVID-19 Outbreak

Africa CDC   [to 16 Apr 2022]
http://www.africacdc.org/
News
No new digest content identified.
China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 16 Apr 2022]
http://en.nhc.gov.cn/

News
April 16: Daily briefing on novel coronavirus cases in China
On April 15, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 3,896 new cases of confirmed infections.

National Medical Products Administration – PRC [to 16 Apr 2022]
http://english.nmpa.gov.cn/

News
Chinese mainland reports 3,472 new local COVID-19 cases, 3,200 in Shanghai
2022-04-15
The Chinese mainland Thursday reported 3,472 locally-transmitted confirmed COVID-19 cases, of which 3,200 were in Shanghai, according to the National Health Commission (NHC)'s report Friday.

Over 3.3b COVID-19 vaccine doses administered on Chinese mainland
2022-04-13
Over 3.3 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of April 11, data from the National Health Commission showed on April 12.

CCDC Weekly Reports: Current Volume (4)
022-04-15 / No. 15 NATIONAL ANTI-CANCER WEEK ISSUE
View PDF of this issue
Foreword: Cancer Prevention and Early Action
Preplanned Studies: Burden of Disease Due to Cancer — China, 2000–2019
Preplanned Studies: Economic Burden of Malignant Tumors — Yichang City, Hubei Province, China, 2019
Vital Surveillances: Cancer Mortality and Cause Eliminated Life Expectancy in Key Areas of Four Provinces — China, 2008–2018
Perspectives: Colorectal Cancer Screening in China: Status, Challenges, and Prospects — China, 2022

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Error! Reference source not found.:: Organization Announcements
:: Journal Watch
**Organization Announcements**

*Editor’s Note:*
Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

**Airfinity**  [to 16 Apr 2022]
https://www.airfinity.com/insights
*INSIGHTS & COMPANY NEWS*
**Airfinity downgrades its global COVID-19 vaccine revenue forecast to $64.1B**
Published by Airfinity
Apr 10, 2022
Airfinity has downgraded its global sales forecast for COVID-19 vaccines this year from $80.8bn to $64.1bn.

**Paul G. Allen Frontiers Group**  [to 16 Apr 2022]
https://alleninstitute.org/news-press/
*News*
No new digest content identified.

**BMGF - Gates Foundation**  [to 16 Apr 2022]
https://www.gatesfoundation.org/ideas/media-center
*Press Releases and Statements*
No new digest content identified.

**Bill & Melinda Gates Medical Research Institute**  [to 16 Apr 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

**CARB-X**  [to 16 Apr 2022]
https://carb-x.org/
*News*
No new digest content identified.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation**  [to 16 Apr 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of *Vaccines and Global Health: The Week in Review* are available here.

:: **Informed Consent: A Monthly Review – April 2022** is now posted [here](#).

:: **Statement on ICF [Informed Consent Form] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse**

:: **Patients, Politics, Pressure :: Pharma Stays Steady [Mostly] In Russia Sanctions Context Observations at 30 March 2022** David R Curry

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 16 Apr 2022]
http://cepi.net/
*Latest News*
*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 16 Apr 2022]
https://www.darpa.mil/news
*News*
*No new digest content identified.*

**Duke Global Health Innovation Center** [to 16 Apr 2022]
https://dukeghic.org/
*Our Blog*
*No new digest content identified.*

**EDCTP** [to 16 Apr 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
*News*
*No new digest content identified.*

**Emory Vaccine Center** [to 16 Apr 2022]
http://www.vaccines.emory.edu/
*Vaccine Center News*
*No new digest content identified.*

**European Vaccine Initiative** [to 16 Apr 2022]
Evidence Aid  [to 16 Apr 2022]  
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use. 
http://www.evidenceaid.org/ 
New Resources 
No new digest content identified.

Fondation Merieux  [to 16 Apr 2022]  
http://www.fondation-merieux.org/ 
News, Events 
Mérieux Foundation & University of Geneva co-organized event  
**22nd Advanced Vaccinology Course (ADVAC)** 
May 9 - 20, 2022 - Les Pensières Center for Global Health, Veyrier-du-Lac (France)

Gavi  [to 16 Apr 2022]  
https://www.gavi.org/ 
News Releases 
No new digest content identified.

GHIT Fund  [to 16 Apr 2022]  
https://www.ghitfund.org/newsroom/press 
Press Releases 
No new digest content identified.

Global Fund  [to 16 Apr 2022]  
News & Stories 
No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 16 Apr 2022]  
https://www.glopid-r.org/news/ 
News 
No new digest content identified

Hilleman Laboratories  [to 16 Apr 2022]  
http://www.hilleman-labs.org/
Human Vaccines Project [to 16 Apr 2022]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

IAVI [to 16 Apr 2022]
https://www.iavi.org/
Latest News
No new digest content identified.

ICRC [to 16 Apr 2022]
What's New  [Selected]
Equitable access to COVID-19 vaccination is a humanitarian imperative
12-04-2022 | Statement
[See COVID above for detail]

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC  [to 16 Apr 2022]
Press Releases [Selected]
14/04/2022
**Tonga: Red Cross tackles triple disaster - COVID-19, volcanic fallout, tsunami**

14/04/2022
**IFRC to support more than 2 million people affected by the conflict in Ukraine with its largest ever**

**Institut Pasteur** [to 16 Apr 2022]
*Press Documents*
*Press release* 14.04.2022
**Decoding a direct dialog between the gut microbiota and the brain**
Gut microbiota by-products circulate in the bloodstream, regulating host physiological processes including immunity, ...

*Press release* 13.04.2022
**Colon cancer: how mutation of the APC gene disrupts lymphocyte migration**
In patients with familial adenomatous polyposis, a genetic disease predisposing to colon cancer, mutations of the APC...

*Press release* 12.04.2022
**HIV: The Antibodies of "Post-treatment Controllers"**
A very small percentage of people with HIV-1, known as "post-treatment controllers" (PTCs), are able to control their...

**IOM / International Organization for Migration** [to 16 Apr 2022]
*News - Selected*
*No new digest content identified.*

**ISC / International Science Council** [to 16 Apr 2022]
https://council.science/current/
*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*
*News Blogs Podcasts Events*
*Blogs*
**A call to ISC Members: how to assist displaced Ukrainian scholars**
11.04.2022

**IVAC** [to 16 Apr 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
*Updates; Events*
**World Immunization Week 2022: Webinars**
April 2022

During World Immunization Week 2022 the International Vaccine Access Center, along with global immunization and indigenous health partners, will host a three webinars. Registration is free, and we encourage all to sign up and save these dates on their calendars. Enabling Equitable Access to COVID-19 Vaccines for Indigenous Populations When: April 26, 2022 from 6:00 [...]
OECD [to 16 Apr 2022]
http://www.oecd.org/newsroom/publicationsdocuments/bydate/
Newsroom/Library
COVID-19 assistance to developing countries lifts foreign aid in 2021 - OECD
Foreign aid from official donors rose to an all-time high of USD 179 billion in 2021, up 4.4% in real terms from 2020 as developed countries stepped up their help for developing countries grappling with the COVID-19 crisis, according to preliminary data collected by the OECD.

PATH [to 16 Apr 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Sabin Vaccine Institute [to 16 Apr 2022]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 16 Apr 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
14 April 2022
Life-saving logistics in Ukraine

UNHCR Office of the United Nations High Commissioner for Refugees [to 16 Apr 2022]
Selected News Releases, Announcements
UN Refugee Agency opposes UK plan to export asylum
14 Apr 2022
Spiraling costs, surging conflict, and soaring climate disasters create a desperate future for millions of refugees across Eastern Africa
WFP and UNHCR Joint News Release
13 Apr 2022
Statement on risks of trafficking and exploitation facing refugees from Ukraine attributed to UNHCR’s Assistant High Commissioner for Protection
The following statement is attributed to Gillian Triggs, UNHCR’s Assistant High Commissioner for Protection
12 Apr 2022
"We must take the rapid action needed to accelerate vaccination."

[See COVID above for detail]
The Wistar Institute  [to 16 Apr 2022]
Press Releases
No new digest content identified.

WFPHA: World Federation of Public Health Associations  [to 16 Apr 2022]
https://www wfpha.org/
Latest News - Blog
No new digest content identified.

World Bank  [to 16 Apr 2022]
Selected News, Announcements
Green Fiscal Reforms can Protect Vulnerable Households and Boost COVID-19 Recovery Efforts in Europe
BRUSSELS, April 14, 2022 - Green fiscal reforms can help protect vulnerable households and support pandemic recovery efforts in European countries on the road to climate neutrality by 2050, says a new...
Date: April 14, 2022 Type: Press Release

Joint Statement: The Heads of the World Bank Group, IMF, WFP, and WTO Call for Urgent Coordinated Action on Food Security
Proposed actions to help vulnerable countries include providing emergency food supplies and deploying financial support to households and countries; facilitating unhindered trade; investing in sustainable...
Date: April 13, 2022 Type: Press Release

Joint Statement: The Heads of the World Bank Group, IMF, WFP, and WTO Call for Urgent Coordinated Action on Food Security
Proposed actions to help vulnerable countries include providing emergency food supplies and deploying financial support to households and countries; facilitating unhindered trade; investing in sustainable...
Date: April 13, 2022 Type: Statement

World Customs Organization – WCO  [to 16 Apr 2022]
http://www.wcoomd.org/
Latest News
No new digest content identified.

World Organisation for Animal Health (OIE)  [to 16 Apr 2022]
WTO - World Trade Organisation [to 16 Apr 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events [Selected]
World Bank, IMF, WFP and WTO call for urgent coordinated action on food security
13 April 2022
The heads of the World Bank, the International Monetary Fund (IMF), the United Nations World Food Program (WFP) and the WTO issued a joint statement on 13 April urging coordinated action to help vulnerable countries address growing threats to food security. The proposed actions include providing emergency food supplies and deploying financial support to households and countries, facilitating unhindered trade, and investing in sustainable food production and nutrition security.

WHO, WIPO, WTO launch trilateral COVID-19 technical assistance platform
11 April 2022
The World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO launched on 11 April 2022 their new Trilateral COVID-19 Technical Assistance Platform. This new tool aims to help members and WTO accession candidates address their capacity building needs to respond to the COVID-19 pandemic.
[See COVID above for detail]

-----

ARM [Alliance for Regenerative Medicine] [to 16 Apr 2022]
Selected Press Releases
No new digest content identified.

BIO [to 16 Apr 2022]
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 16 Apr 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 16 Apr 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.
IFPMA [to 16 Apr 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
COVID-19 vaccines and treatments output continues apace; as health systems and last mile hurdles remain
13 April 2022
[See COVID above for detail]

IFPMA statement at public hearings regarding a new international instrument on pandemic preparedness and response
13 April 2022
The biopharmaceutical industry is committed to working with stakeholders to improve pandemic preparedness for the future and to ensure equitable access to medical countermeasures.

Any system should be built on what worked well during the COVID-19 pandemic with robust IP frameworks enabling collaborations, as well as immediate sharing of pathogens.

As the INB enters deeper discussions on a new instrument we believe these should be informed by a few core principles:
1. The negotiation process should be inclusive and transparent, involving private sector and all critical contributors to PPR efforts
2. In the spirit of subsidiarity, tasks and decision-making processes which are more efficiently performed nationally or regionally should remain at these levels.
3. We call for clarity on roles and expectations, improving forecast and reducing unnecessary red tape
4. Any new system should be complementary to existing instruments and include clarifications on how it relates to other existing frameworks
5. Any system should allow for immediate open access of pathogens and genetic sequence data and correct the negative effects of access and benefit-sharing legislation.
6. Promote equitable access to diagnostics, treatments and vaccines based on medical need, enhancing solidarity and facilitating emergency financing to institutions procuring for developing countries like COVAX.
7. Supply chains should be protected from arbitrary export restrictions and other trade barriers
8. The system should build on the private sector’s strengths for R&D, manufacturing and distribution, and overall support innovation

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

International Alliance of Patients’ Organizations – IAPO [to 16 Apr 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 1
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 4: E249-341 Apr 2022
https://journalofethics.ama-assn.org/issue/health-equity-us-latinx-communities

Health Equity in US Latinx Communities
Latinx communities in the US include over 60 million people with a plurality of political beliefs, cultural practices, and wealth. This diversity is also expressed in population health data: some health indicators suggest advantages of Latinx community membership while other data demonstrate inequitable disease burden and maldistribution of environmental and occupational risk. Legacies of colonial conquest of the Americas persist in discrimination and marginalization today and are embodied by members of our Latinx communities.
**BMC Health Services Research**
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 16 Apr 2022)

**Studying SARS-CoV-2 vaccine hesitancy among health professionals in Tunisia**

*People's lives were seriously affected by the emergence and the spread of the COVID-19 disease. Several vaccines were developed in record time to overcome this pandemic. However, putting an end to this public...*

Authors: Nawel Zammit, Amani El Gueder, Aïcha Brahaim, Imen Ayouni, Rim Ghammam, Sihem Ben Fredj, Chaima Sridi, Asma Chouchene, Houda Kalboussi, Olfa El Maalel, Souheil Chatbi, Jihene Maatouq, Hassen Ghannem and Néjib Mrizak

Citation: BMC Health Services Research 2022 22:489
Content type: Research Published on: 12 April 2022

---

**BMC Infectious Diseases**
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 16 Apr 2022)

**Children with SARS-CoV-2 infection during the novel coronaviral disease (COVID-19) outbreak in Iran: an alarming concern for severity and mortality of the disease**

*The rapid worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections led to public health crises globally and the number of pediatric patients with Coronavirus Disease 2019 (CO...*

Authors: Setareh Mamishi, Babak Pourakbari, Mehrzad Mehdizadeh, Amene Navaeian, Hamid Eshaghi, Bahareh Yaghmaei, Reihaneh Hosseinipour Sadeghi, Shiva Poormohammadi, Yasmine Mahmoudieh and Shima Mahmoudi

Citation: BMC Infectious Diseases 2022 22:382
Content type: Research article Published on: 15 April 2022

---

**Determinants of measles vaccination dropout among 12 – 23 months aged children in pastoralist community of Afar, Ethiopia**

*Measles is a viral disease and a leading vaccine-preventable childhood killer. More than 95% of measles deaths occur in countries with low incomes and weak health infrastructures. In response to this, Ethiopia...*

Authors: Chekole Hailu, Girmatsion Fisseha and Aregawi Gebreyesus

Citation: BMC Infectious Diseases 2022 22:376
Content type: Research article Published on: 14 April 2022

---

**BMC Medical Ethics**
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 16 Apr 2022)

[No new digest content identified]

---

**BMC Medicine**
http://www.biomedcentral.com/bmcmed/content
(Accessed 16 Apr 2022)

[No new digest content identified]
Barriers to and strategies to address COVID-19 testing hesitancy: a rapid scoping review

Testing is a foundational component of any COVID-19 management strategy; however, emerging evidence suggests that barriers and hesitancy to COVID-19 testing may affect uptake or participation and often these a...

Authors: Mark Embrett, S. Meaghan Sim, Hilary A. T. Caldwell, Leah Boulos, Ziwa Yu, Gina Agarwal, Rhiannon Cooper, Allyson J. Gallant AJ, Iwona A. Bielska, Jawad Chishtie, Kathryn Stone, Janet Curran and Andrea Tricco

Citation: BMC Public Health 2022 22:750
Content type: Research Published on: 14 April 2022

Considering social inequalities in health in large-scale testing for COVID-19 in Montréal: a qualitative case study

Evidence continues to demonstrate that certain marginalised populations are disproportionately affected by COVID-19. While many studies document the impacts of COVID-19 on social inequalities in health, none h...

Authors: Marie-Catherine Gagnon-Dufresne, Lara Gautier, Camille Beaujoin, Ashley Savard Lamothe, Rachel Mikanagu, Patrick Cloos, Valéry Ridde and Kate Zinszer

Citation: BMC Public Health 2022 22:749
Content type: Research Published on: 14 April 2022

Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar

While mass COVID-19 vaccination programs are underway in high-income countries, limited availability of doses has resulted in few vaccines administered in low and middle income countries (LMICs). The COVID-19 ...

Authors: Fidisoa Rasambainarivo, Tanjona Ramiadantsoa, Antso Raherinandrason, Santatra Randrianarisoa, Benjamin L. Rice, Michelle V. Evans, Benjamin Roche, Fidiniaina Mamy Randriatsarafara, Amy Wesolowski and Jessica C. Metcalf

Citation: BMC Public Health 2022 22:724
Content type: Research Published on: 12 April 2022

A network of change: united action on research integrity

Authors: Thomas Rhys Evans, Madeleine Pownall, Elizabeth Collins, Emma L. Henderson, Jade S. Pickering, Aoife O’Mahony, Mirela Zaneva, Matt Jaquier and Tsvetomira Dumbalska
Abstract
The last decade has seen renewed concern within the scientific community over the reproducibility and transparency of research findings. This paper outlines some of the various responsibilities of stakeholders in addressing the systemic issues that contribute to this concern. In particular, this paper asserts that a united, joined-up approach is needed, in which all stakeholders, including researchers, universities, funders, publishers, and governments, work together to set standards of research integrity and engender scientific progress and innovation. Using two developments as examples: the adoption of Registered Reports as a discrete initiative, and the use of open data as an ongoing norm change, we discuss the importance of collaboration across stakeholders.

BMJ Evidence-Based Medicine
April 2022 - Volume 27 - 2
https://ebm.bmj.com/content/27/2
[Reviewed earlier]

BMJ Open
April 2022 - Volume 12 - 4
https://bmjopen.bmj.com/content/12/4
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 100(4); 2022 Apr 1
https://www.ncbi.nlm.nih.gov/pmc/issues/404046/
[Reviewed earlier]

Cell
Apr 14, 2022 Volume 185 Issue 8 p1261-1444
https://www.cell.com/cell/current
Conversations
Learning lessons from lipids to make COVID-19 vaccines
A game-changing intervention in the COVID-19 pandemic has been the rapid implementation of highly effective vaccines against SARS-CoV-2. The 2022 Canada Gairdner International Award recognizes Pieter Cullis, Katalin Karikó, and Drew Weissman “for their pioneering work developing nucleoside-modified mRNA and lipid nanoparticle (LNP) drug delivery: the foundational technologies for the highly effective COVID-19 mRNA vaccines.” Cell editor Cheri Sirois caught up with Pieter to discuss how a long interest in basic and applied questions in lipid biology led to this fortuitous collaboration. Excerpts of the conversation are presented below.

Voices
The voices of Ukrainian and Russian scientists
Rostyslav Stoika, Nikita Gudimchuk, Halyna R. Shcherbata, Andrey Zaraisky, Oleksandr Shcheglovitov, Yevgenia Kozorovitskiy, Viktor Korolchuk
The brutal attack on Ukraine by the Russian Federation has shocked the world. While the world works to end the violence and help refugees, as a scientific journal, our thoughts are also with those in the scientific community who are directly or indirectly impacted by the war. We have been inspired by and applaud the labs around the world that have opened their doors to displaced scientists and remain committed to supporting scientists, whoever and wherever they are. Because science requires collaboration and trust, we urge the scientific community to continue efforts like this and to remain united, especially in times as difficult as these. In this Voices piece, we feature short comments from scientists from Ukraine and scientists from Russia. This small sampling is far from exhaustive, but our sincere thanks go to those scientists who were willing to share their thoughts on this volatile and emotionally charged situation; the views expressed are those of the contributors alone. We join the world in hoping for a swift resolution to the conflict, for the good of humanity.

**Child Care, Health and Development**
Volume 48, Issue 3  Pages: 359-511  May 2022
[Reviewed earlier]
https://onlinelibrary.wiley.com/toc/13652214/current

**Clinical Pharmacology & Therapeutics**
Volume 111, Issue 4  Pages: 705-971  April 2022
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

**Therapeutic Innovations in Neuroscience**
The theme of this issue of *Clinical Pharmacology & Therapeutics* (CPT) encompasses neuroscience in the broad sense to include neurology and psychiatry, nonclinical and clinical aspects, novel clinical trial methodologies, and modeling and simulation approaches applicable to central nervous system (CNS) drug development and therapy. While naturally the last two years have been dominated by coronavirus disease 2019 (COVID-19), it is important not to forget that drug development for other indications has not been stopped, albeit many trials were affected in terms of delays in recruitment and collection of clinical data.

**Clinical Therapeutics**
February 2022  Volume 44  Issue 2  p155-348
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

**Clinical Trials**
Volume 19 Issue 1, February 2022
https://journals.sagepub.com/toc/ctja/19/1
[Reviewed earlier]

**Conflict and Health**
http://www.conflictandhealth.com/
[Accessed 16 Apr 2022]
[No new digest content identified]
Contemporary Clinical Trials  
Volume 114  March 2022  
[Reviewed earlier]

The CRISPR Journal  
Volume 5, Issue 1 / February 2022  
https://www.liebertpub.com/toc/crispr/5/1  
[Reviewed earlier]

Current Genetic Medicine Reports  
Volume 9, issue 4, December 2021  
https://link.springer.com/journal/40142/volumes-and-issues/9-4  
[Reviewed earlier]

Current Opinion in Infectious Diseases  
April 2022 - Volume 35 - Issue 2  
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx  
[Reviewed earlier]

Current Protocols in Human Genetics  
Volume 108, Issue 1  December 2020  
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current  
[Reviewed earlier]

Developing World Bioethics  
Volume 22, Issue 1  Pages: 1-62  March 2022  
https://onlinelibrary.wiley.com/toc/14718847/current  
[Reviewed earlier]

Development in Practice  
Volume 32, Issue 1, 2022  
http://www.tandfonline.com/toc/cdip20/current  
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness  
Volume 15 - Issue 6 - December 2021  
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
Volume 21 (April 2022)
[New issue; No digest content identified]

The European Journal of Public Health
Volume 32, Issue 2, April 2022
https://academic.oup.com/eurpub/issue/32/2
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (4) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 1
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 16 Apr 2022]
[No new digest content identified]

Global Health Action
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
Vol. 10, No. 1  February 28, 2022
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 16 Apr 2022]
[No new digest content identified]

Global Public Health
What is the impact of intellectual property rules on access to medicines? A systematic review

It is widely accepted that intellectual property legal requirements such as patents and data exclusivity can affect access to medicines, but to date there has not been a comprehensive review of the empirical evidence.

Authors: Brigitte Tenni, Hazel V. J. Moir, Belinda Townsend, Burcu Kilic, Anne-Maree Farrell, Tessa Keegel and Deborah Gleeson

Citation: Globalization and Health 2022 18:40
Content type: Review Published on: 15 April 2022

Health and Human Rights
Volume 23, Issue 2, December 2021
https://www.hhrjournal.org/volume-23-issue-2-december-2021/
[Reviewed earlier]

Health Economics, Policy and Law
Volume 17 - Issue 2 - April 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 37, Issue 3, March 2022
https://academic.oup.com/heapol/issue/37/3
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 16 Apr 2022]
[No new digest content identified]

Human Gene Therapy
Volume 33, Issue 5-6 / March 2022
https://www.liebertpub.com/toc/hum/33/5-6
[Reviewed earlier]
Humanitarian Practice Network
https://odihpn.org/
*Online Article*
[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 18, Issue 1, 2022
https://www.tandfonline.com/toc/khvi20/current
[Reviewed earlier]

**Immunity**
Apr 12, 2022  Volume 55  Issue 4  p575-734
https://www.cell.com/immunity/current
[New issue; No digest content identified]

**Infectious Agents and Cancer**
http://www.infectagentscancer.com/
[Accessed 16 Apr 2022]
[No new digest content identified]

**Infectious Diseases of Poverty**
http://www.idpjournal.com/content
[Accessed 16 Apr 2022]
[No new digest content identified]

**International Health**
Volume 14, Issue 2, March 2022
https://academic.oup.com/inthealth/issue/14/2
[Reviewed earlier]

**International Human Rights Law Review**
Volume 10 (2021): Issue 2 (Dec 2021)
https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml
[Reviewed earlier]

**International Journal of Community Medicine and Public Health**
Vol 9, No 1 (2022)  January 2022
https://www.ijcmph.com/index.php/ijcmph/issue/view/84
[Reviewed earlier]
International Journal of Epidemiology
Volume 51, Issue 1, February 2022
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 14 Issue 5 2021
https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5
Table of Contents
[Reviewed earlier]

JAMA
Apr 12, 2022 Volume 55 Issue 4 p575-734
https://jamanetwork.com/journals/jama/currentissue
[New issue; No digest content identified]

JAMA Network
COVID-19 Update  April 16, 2022
These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics
April 2022, Vol 176, No. 4, Pages 335-428
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
March 2022 - Volume 20 - Issue 3
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
April 2022 Volume 70 Issue 4 p517-696
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 73 (2022)
https://www.jair.org/index.php/jair
[Reviewed earlier]
**Journal of Community Health**
Volume 47, issue 2, April 2022  
[Reviewed earlier]

**Journal of Development Economics**
Volume 156, May 2022  
[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**
Volume 17 Issue 1-2, February-April 2022  
http://journals.sagepub.com/toc/jre/current  
[Reviewed earlier]

**Journal of Epidemiology & Community Health**
April 2022 - Volume 76 - 4  
https://jech.bmj.com/content/76/4  
Commentary  
Assessment of the proposed intellectual property waiver as a mechanism to address the COVID-19 vaccine scarcity problem (9 February, 2022)
Julia Barnes-Weise, Ana Santos Rutschman, Reid Adler

**Journal of Evidence-Based Medicine**
Volume 15, Issue 1 Pages: 1-72 March 2022  
https://onlinelibrary.wiley.com/toc/17565391/current  
ARTICLES  
An overview of methodological approaches in systematic reviews  
Prabhakar Veginadu, Hanny Calache, Mark Gussy, Akshaya Pandian, Mohd Masood  
Pages: 39-54  
First Published: 13 April 2022

**Journal of Global Ethics**
Volume 17, Issue 3, 2021  
http://www.tandfonline.com/toc/rjge20/current  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**
Volume 33, Number 1, February 2022  
https://muse.jhu.edu/issue/47329  
Table of Contents
REVIEW
Waning Immunity After Receipt of Pertussis, Diphtheria, Tetanus, and Polio-Related Vaccines: A Systematic Review and Meta-analysis
Huizhi Gao, Eric H Y Lau, Benjamin J Cowling
Our results supported the notion that secondary vaccine failure may be the reason for reemergence of pertussis and diphtheria. Tetanus and polio vaccines provided more sustained protection.

MAJOR ARTICLES AND BRIEF REPORTS
COVID-19 Vaccination Rates in a Global HIV Cohort
Evelynne S Fulda, Kathleen V Fitch, Edgar T Overton, Markella V Zanni, Judith A Aberg ...

Journal of Medical Ethics
April 2022 - Volume 48 - 4
http://jme.bmj.com/content/current
[Reviewed earlier]
http://www.jpeds.com/current
[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**
https://joppp.biomedcentral.com/
[Accessed 16 Apr 2022]
[No new digest content identified]

**Journal of Public Health Management & Practice**
May/June 2022 - Volume 28 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[New issue; No digest content identified]

**Journal of Public Health Policy**
Volume 43, issue 1, March 2022
https://link.springer.com/journal/41271/volumes-and-issues/43-1
[Reviewed earlier]

**Journal of Refugee & Global Health**
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

**Journal of the Royal Society – Interface**
April 2022  Volume 19  Issue 189
https://royalsocietypublishing.org/toc/rsif/current
[New issue; No digest content identified]

**Journal of Travel Medicine**
Volume 29, Issue 2, March 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

**Journal of Virology**
Volume 96  Number 4  February 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

**The Lancet**
Apr 16, 2022 Volume 399 Number 10334  p1441-1572, e37
https://www.thelancet.com/journals/lancet/issue/current
Comment

Understanding of COVID-19 from infection–fatality ratio
Xiaoying Gu, Bin Cao

Understanding of COVID-19 from infection–fatality ratio
Xiaoying Gu, Bin Cao

Articles

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis
COVID-19 Forecasting Team
Open Access

Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021
COVID-19 National Preparedness Collaborators
Open Access

COVID-19 Excess Mortality Collaborators
Open Access

The Lancet Child & Adolescent Health
Apr 2022 Volume 6 Number 4 p215-278, e13-e15
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Apr 2022 Volume 4 Number 4 e207-e289
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
Apr 2022 Volume 10 Number 4 e448-e584
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Apr 2022 Volume 22 Number 4p 427-562, e101-e127
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]
**Lancet Public Health**  
Apr 2022 Volume 7 Number 4 e291-e390  
https://www.thelancet.com/journals/lanpub/issue/current  
[Reviewed earlier]

**Lancet Respiratory Medicine**  
Apr 2022 Volume 10 Number 4 p313-420, e34-e43  
https://www.thelancet.com/journals/lanres/issue/current  
[Reviewed earlier]

**Maternal and Child Health Journal**  
Volume 26, issue 3, March 2022  
[Reviewed earlier]

**Medical Decision Making (MDM)**  
Volume 42 Issue 3, April 2022  
http://mdm.sagepub.com/content/current  
[New issue; No digest content identified]

**The Milbank Quarterly**  
*A Multidisciplinary Journal of Population Health and Health Policy*  
Volume 100, Issue 1 Pages: 1-313 March 2022  
https://onlinelibrary.wiley.com/toc/14680009/current  
[New issue; No digest content identified]

**Nature**  
Volume 604 Issue 7905, 14 April 2022  
https://www.nature.com/nature/volumes/604/issues/7905  
*Analysis* | 06 April 2022 | Open Access  
**A joint NCBI and EMBL-EBI transcript set for clinical genomics and research**  
Matched Annotation from NCBI and EMBL-EBI (MANE) delivers joint transcript sets from Ensembl/GENCODE and RefSeq for standardizing variant reporting in clinical genomics and research. Joannella Morales, Shashikant Pujar, Terence D. Murphy

**Nature Biotechnology**  
Volume 40 Issue 4, April 2022  
https://www.nature.com/nbt/volumes/40/issues/4  
*Editorial* | 04 April 2022  
**Licensing for profit and for good**
The Broad Institute’s enlightened licensing approach to CRISPR–Cas9 intellectual property stands out in the otherwise regrettable spat for patent rights over the foundational technology.

**Nature Communications**
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 16 Apr 2022)
[No new digest content identified]

**Nature Genetics**
Volume 54 Issue 4, April 2022
https://www.nature.com/ng/volumes/54/issues/4
Article | 11 April 2022
**Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects**
GWASs based on self-reported phenotypes in 736,723 individuals show distinct associations between risk loci and eight COVID-19 outcomes, suggesting differences in genetic susceptibility to infection upon exposure and severe and symptomatic disease.
Genevieve H. L. Roberts, Raghavendran Partha, Kristin A. Rand
Analysis | 28 March 2022 | Open Access
**Global landscape of SARS-CoV-2 genomic surveillance and data sharing**
Analyses on the global diversity of SARS-CoV-2 genomic surveillance across 118 countries and the extent of public availability of genomic data provide evidence to better inform SARS-CoV-2 surveillance policy.
Zhiyuan Chen, Andrew S. Azman, Hongjie Yu

**Nature Human Behaviour**
Volume 6 Issue 3, March 2022
https://www.nature.com/nathumbehav/volumes/6/issues/3
[Reviewed earlier]

**Nature Medicine**
Volume 28 Issue 3, March 2022
https://www.nature.com/nm/volumes/28/issues/3
[Reviewed earlier]

**Nature Reviews Genetics**
Volume 23 Issue 4, April 2022
https://www.nature.com/nrg/volumes/23/issues/4
[Reviewed earlier]

**Nature Reviews Immunology**
Biosecurity in an age of open science
James Andrew Smith, Jonas B. Sandbrink
Essay | published 14 Apr 2022 PLOS Biology
https://doi.org/10.1371/journal.pbio.3001600
Abstract
The risk of accidental or deliberate misuse of biological research is increasing as biotechnology advances. As open science becomes widespread, we must consider its impact on those risks and
develop solutions that ensure security while facilitating scientific progress. Here, we examine the interaction between open science practices and biosecurity and biosafety to identify risks and opportunities for risk mitigation. Increasing the availability of computational tools, datasets, and protocols could increase risks from research with misuse potential. For instance, in the context of viral engineering, open code, data, and materials may increase the risk of release of enhanced pathogens. For this dangerous subset of research, both open science and biosecurity goals may be achieved by using access-controlled repositories or application programming interfaces. While preprints accelerate dissemination of findings, their increased use could challenge strategies for risk mitigation at the publication stage. This highlights the importance of oversight earlier in the research lifecycle. Preregistration of research, a practice promoted by the open science community, provides an opportunity for achieving biosecurity risk assessment at the conception of research. Open science and biosecurity experts have an important role to play in enabling responsible research with maximal societal benefit.

**PLoS Genetics**
[https://journals.plos.org/plosgenetics/](https://journals.plos.org/plosgenetics/)  
(Accessed 16 Apr 2022)  
[No new digest content identified]

**PLoS Medicine**
(Accessed 16 Apr 2022)  
[No new digest content identified]

**PLoS Neglected Tropical Diseases**
[http://www.plosntds.org/](http://www.plosntds.org/)  
(Accessed 16 Apr 2022)  
[No new digest content identified]

**PLoS One**
[Accessed 16 Apr 2022]  
*Research Article*
**A scholarly network of AI research with an information science focus: Global North and Global South perspectives**
Kai-Yu Tang, Chun-Hua Hsiao, Gwo-Jen Hwang  
Research Article | published 15 Apr 2022 PLOS ONE  
[https://doi.org/10.1371/journal.pone.0266565](https://doi.org/10.1371/journal.pone.0266565)

**PLoS Pathogens**
[http://journals.plos.org/plospathogens/](http://journals.plos.org/plospathogens/)  
[Accessed 16 Apr 2022]  
[No new digest content identified]
PNAS - Proceedings of the National Academy of Sciences of the United States
April 5, 2022  vol. 119  no. 14
https://www.pnas.org/toc/pnas/119/14
[New issue; No digest content identified]

Prehospital & Disaster Medicine
Volume 37 - Issue 2 - April 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 157  April 2022
[Reviewed earlier]

Proceedings of the Royal Society B
13 April 2022  Volume 289  Issue 1972
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 205  Pages e1-e30, 1-216 (April 2022)
[Reviewed earlier]

Public Health Ethics
Volume 14, Issue 3, November 2021
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 2, March/April 2022
https://journals.sagepub.com/toc/phrg/137/2
[Reviewed earlier]

Qualitative Health Research
Volume 32 Issue 4, March 2022
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]
Research Ethics
Volume 18 Issue 2, April 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 16 Apr 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
Realistic evaluation mechanisms in primary health care interventions in rural and marginal urban populations
Review | Spanish |
13 Apr 2022

Geospatial models for SARS-CoV-2 outbreak control in Cartagena and Barranquilla, Colombia, 2020
Original research | Spanish |
13 Apr 2022

Scientific publication speed and retractions of COVID-19 pandemic original articles
Original research | English |
13 Apr 2022

Management and impact of interventions to reduce COVID-19 cases in Costa Rica
Original research | Spanish |
13 Apr 2022

Risk Analysis
Volume 42, Issue 3  Pages: 429-655  March 2022
https://onlinelibrary.wiley.com/toc/15396924/current
[New issue; No digest content identified]

Risk Management and Healthcare Policy
[Accessed 16 Apr 2022]
Original Research
Acceptance of COVID-19 Vaccine Among High-Risk Occupations in a Port City of China and Multifaceted Strategies for Increasing Vaccination Coverage: A Cross-Sectional Study
Sun Y, Li B, Li N, Li B, Chen P, Hao F, Sun C
Risk Management and Healthcare Policy 2022, 15:643-655
Published Date: 14 April 2022

Science
Volume 376 | Issue 6590 | 15 Apr 2022
https://www.science.org/toc/science/current
Policy Forum
Getting genetic ancestry right for science and society
BY Anna C. F. Lewis, et al.
14 Apr 2022: 250-252
We must embrace a multidimensional, continuous view of ancestry and move away from continental ancestry categories

Science Translational Medicine
Volume 14 | Issue 640 | 13 Apr 2022
https://www.science.org/toc/stm/current
Reviews
Point-of-care diagnostic tests for tuberculosis disease
BY Jia Mei Hong, et al.
06 Apr 2022
Advances in biomarkers and microfluidics technology facilitate the development of TB disease diagnostic point-of-care tests.

Social Science & Medicine
Volume 294 | February 2022
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 16 Apr 2022]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 42, issue 3-4, August 2021
Special Issue: A plea for an experimental philosophy of medicine
[Reviewed earlier]
**Travel Medicine and Infectious Diseases**
Volume 46  March–April 2022
[Reviewed earlier]

**Tropical Medicine & International Health**
Volume 27, Issue 3  Pages: i-iv, 217-336  March 2022
[Reviewed earlier]

**Vaccine**
Volume 40, Issue 13  Pages 1913-2122 (18 March 2022)
[Reviewed earlier]

---

**Epidemiology and economic burden of meningococcal disease in Germany: A systematic review**
S. Gruhn, J. Witte, W. Greiner, O. Damm, ... M. Knuf
Pages 1932-1947

**Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario**
Ga Young Lee, Perapong Inthasorn, Piyawat Laowahutanont, Saranath Lawpoolsri, ... Punnee Pitisuttithum
Pages 1968-1976

**Promoting immunization equity in Latin America and the Caribbean: Case studies, lessons learned, and their implication for COVID-19 vaccine equity**
Isabella L. Chan, Robin Mowson, Juan Pedro Alonso, Javier Roberti, ... Martha Velandia-González

**Impact of the Sinopharm’s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)**
Farida Ismail AlHosani, Anderson Eduardo Stanciole, Bashir Aden, Andrey Timoshkin, ... Farah Mustafa

**Unmet need for COVID-19 vaccination coverage in Kenya**
Samuel K. Muchiri, Rose Muthee, Hellen Kiarie, Joseph Sitienei, ... Victor A. Alegana
Pages 2011-2019

**The correlates and dynamics of COVID-19 vaccine-specific hesitancy**
Eric Merkley, Peter John Loewen
Research article  Open access
"On the last day of the last month, I will go": A qualitative exploration of COVID-19 vaccine confidence among Ivorian adults
Natalie J. Tibbels, Abdul Dosso, Corinne Fordham, William Benie, ... Danielle A. Naugle
Pages 2028-2035

Research article  Full text access
Public perceptions and the willingness to get vaccinated against COVID-19: Lessons from Israel
Oren Heller, Yung Chun, Yaniv Shlomo, Ateret Gewirtz-Meydan, ... Michal Grinstein-Weiss

Research article  Open access
Conspiracy theories and misinformation about COVID-19 in Nigeria: Implications for vaccine demand generation communications
Chizoba Wonodi, Chisom Obi-Jeff, Funmilayo Adewumi, Somto Chloe Keluo-Udeke, ... Ruth Faden

Value in Health
April 2022  Volume 25  Issue 4  p473-676
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles

Open Letter metrics Awaiting Peer Review
Women’s groups and COVID-19: An evidence review on savings groups in Africa [version 1; peer review: awaiting peer review]
Olayinka Adegbite, Leigh Anderson, Sybil Chidiac, Osasuyi Dirisu, Jenna Grzeslo, Julia Hakspiel, Chinmaya Holla, Emily Janoch, Krishna Jafa, Shubha Jayaram, Grace Majara, Tabitha Mulyampiti, Eve Namisango, Eva Noble, Bukola Onyishi, David Panetta, Garima Siwach, Munshi Sulaiman, Rebecca Walcott, Sapna Desai, Thomas de Hoop
Peer Reviewers Invited
Funder
The Bill and Melinda Gates Foundation
PUBLISHED 12 Apr 2022

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

**COVID-19 vaccine coverage among immigrants and refugees in Alberta: a population-based cross-sectional study**
Shannon E MacDonald, Yuba Raj Paudel, Crystal Du
medRxiv 2022.04.11.22273644; doi: https://doi.org/10.1101/2022.04.11.22273644

**Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19**
Athira S Joshy, Christy Thomas, Saphal Surendran, Krishna Undela
medRxiv 2022.04.15.22273881; doi: https://doi.org/10.1101/2022.04.15.22273881

**Mondo: Unifying diseases for the world, by the world**

There are thousands of distinct disease entities and concepts, each of which are known by different and sometimes contradictory names. The lack of a unified system for managing these entities poses a major challenge for both machines and humans that need to harmonize information to better predict causes and treatments for disease. The Mondo Disease Ontology is an open, community-driven ontology that integrates key medical and biomedical terminologies, supporting disease data integration to improve diagnosis, treatment, and translational research. Mondo records the sources of all data and is continually updated, making it suitable for research and clinical applications that require up-to-date disease knowledge.

**Triangulating evidence in health sciences with Annotated Semantic Queries**
Yi Liu, Tom R Gaunt

**Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome**
Effectiveness of COVID-19 vaccines against hospitalization and death in Canada: A multiprovincial test-negative design study
Sharifa Nasreen, Yossi Febriani, Héctor Alexander Velásquez García, Geng Zhang, Mina Tadrous, Sarah A. Buchan, Christiaan H. Righolt, Salaheddin M. Mahmud, Naveed Zafar Janjua, Mel Krajden, Gaston De Serres, Jeffrey C. Kwong

Health Economic Burden of COVID-19 in Saudi Arabia
medRxiv 2022.04.08.22273439; doi: https://doi.org/10.1101/2022.04.08.22273439

Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort study
Matan J Cohen, Yonatan Oster, Allon E Moses, Avishay Spitzer, Shmuel Benenson, the Israeli-hospitals 4th vaccine Working Group
medRxiv 2022.04.11.22273327; doi: https://doi.org/10.1101/2022.04.11.22273327

The relation between COVID-19 vaccinations and public governance to improve preparedness of next pandemic impacts and crisis management: a global study
Mario Coccia, Igor Benati
medRxiv 2022.04.10.22273663; doi: https://doi.org/10.1101/2022.04.10.22273663

Abstract
The goal of this study is to analyze the relationship between COVID-19 vaccinations and public governance performing a global analysis of more than 110 countries worldwide. Methodology applies the Independent Samples T-Test that compares the means of two independent groups (countries with high/low level of vaccinations) to determine whether there is statistical evidence that the associated population means of indicators of public governance are significantly different. Findings suggest that high levels of governance can support a better function of health systems in the rollout of vaccinations to cope with COVID-19 pandemic crisis. This study may assist long-run policy of governments to improve good governance and health systems of countries in order to reinforce the preparedness to face next pandemic threats and in general future crisis management in society.

Economic vulnerability and poor service delivery made it more difficult for shack-dwellers to comply with COVID-19 restrictions: The impracticability and inequitable burden of universal/unstratified public health policies
GTH Ellison, RB Mattes, H Rhoma, T De Wet
medRxiv 2022.04.07.22273499; doi: https://doi.org/10.1101/2022.04.07.22273499

COVID-19 vaccine for people who live and work in prisons worldwide: A scoping review
Nasrul Ismail, Lara Tavoschi, Babak Moazeni, Alicia Roselló, Emma Plugge
medRxiv 2022.04.07.22273414; doi: https://doi.org/10.1101/2022.04.07.22273414


**Novel Privacy Considerations for Large Scale Proteomics**
medRxiv 2022.04.06.22269907; doi: https://doi.org/10.1101/2022.04.06.22269907

**COVID-19 Vaccination Mandates and Vaccine Uptake**
Alexander Karaivanov, Dongwoo Kim, Shih En Lu, Hitoshi Shigeoka
medRxiv 2021.10.21.21265355; doi: https://doi.org/10.1101/2021.10.21.21265355 Revision

**Acceptance of and preference for COVID-19 vaccination in healthcare workers: a comparative analysis and discrete choice experiment**
Chuanxi Fu, Zheng wei, Fengchang Zhu, Sen Pei, Shunping Li, Liuren Zhang, Xiaohui Sun, Yue Wu, Ping Liu, Mark Jit
medRxiv 2020.04.09.20060103; doi: https://doi.org/10.1101/2020.04.09.20060103 Revision

**SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in the northeast of Brazil**
medRxiv 2022.04.08.22272726; doi: https://doi.org/10.1101/2022.04.08.22272726

**Wellcome Open Research** [to 16 Apr 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 16 Apr 2022]
Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

**Data Note metrics AWAITING PEER REVIEW**
**An open dataset of *Plasmodium vivax* genome variation in 1,895 worldwide samples**
[version 1; peer review: awaiting peer review]
Thriemer, Alberto Tobon-Castano, Hidayat Trimarsanto, Marcelo Urbano Ferreira, Ivan D Vélez, Sonam Wangchuk, Thomas E Wellems, Nicholas J White, Timothy William, Maria F Yasnot, Daniel Yilma

Peer Reviewers Invited

Funders
Wellcome Trust
Medical Research Council UK and the Department for International Development (DFID)
Bill and Melinda Gates Foundation

PUBLISHED 14 Apr 2022

Research Article metrics
Revised

**Stage 2 Registered Report: How responsibility attributions to self and others relate to outcome ownership in group decisions** [version 2; peer review: 2 approved]

Matt Jaquiery, Marwa El Zein

Peer Reviewers John A. Dewey; Nura Sidarus

Funders
Wellcome Trust
Medical Research Council
University of Oxford

LATEST VERSION PUBLISHED 11 Apr 2022

Research Article metrics
Revised

**A survey to gather perspectives of DBT/Wellcome Trust India Alliance-funded researchers on public engagement with science** [version 2; peer review: 2 approved]

Sarah Iqbal, Banya Kar

Peer Reviewers Marina Joubert; Mary Chambers and Han Dong Thai Tran

Funder

DBT/Wellcome Trust India Alliance

LATEST VERSION PUBLISHED 08 Apr 2022

* * * * *

**Think Tanks**

**Brookings**
http://www.brookings.edu/
Accessed 16 Apr 2022

[No new digest content identified]

**Center for Global Development** [to 16 Apr 2022]
https://www.cgdev.org/
Research [Selected]
POLICY PAPERS

**Beyond India’s Lockdown: PMGKY Benefits During the COVID-19 Crisis and the State of Digital Payments**
India imposed a lock-down in response to the COVID-19 pandemic in March 2020 and began a gradual re-opening in June. A telephonic survey in April examined the early effectiveness of information and the massive PMGKY social protection program (Policy Paper 217). This paper analyzes a second-round sur...

**Chatham House**  [to 16 Apr 2022]
https://www.chathamhouse.org/
*Accessed 16 Apr 2022*
[No new digest content identified]

**CSIS**
https://www.csis.org/
*Accessed 16 Apr 2022*

**Upcoming Event**
**Equity in Immunization Services to Ensure “A Long Life for All”**
April 28, 2022

**Upcoming Event**
**Innovation and IP’s Role in Combatting the Covid-19 Pandemic**
April 27, 2022

**Upcoming Event**
**AMR as a Global Security Threat: Destabilizing Food Systems and Healthy Communities**
April 25, 2022

**Commentary**
**Removing Patent Rights to Lower Drug Costs Is a Dangerous Precedent**
April 14, 2022 | By Walter G. Copan

**Kaiser Family Foundation**
https://www.kff.org/search/?post_type=press-release
*Accessed 16 Apr 2022*
*Accessed 16 Apr 2022*
[No new digest content identified]

**ODI [Overseas Development Institute]**  [to 16 Apr 2022]
*Accessed 16 Apr 2022*
[No new digest content identified]
**Rand** [to 16 Apr 2022]
https://www.rand.org/pubs.html

*Reports, Selected Journal Articles*

**Report**

**How Extremism Operates Online: A Primer**

In this Perspective, the second in a RAND Corporation series on online extremist material, the authors explore how the internet affects extremist activities and how exposure to or consumption of such content influences the behavior of internet users.

Apr 12, 2022
Alexandra T. Evans, Heather J. Williams

* * * * *
* * * * *

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).
Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.